The Chemoinformatics Market size is estimated at USD 6.10 billion in 2024, and is expected to reach USD 10.90 billion by 2029, growing at a CAGR of 15.5% during the forecast period (2024-2029).
The pandemic positively impacted the cheminformatics market. The outbreak of the COVID-19 pandemic pushed the pharmaceutical industry into action, with a race to develop both therapeutic and preventive drugs. Cheminformatics approaches are one set of tools in the computational toolbox that can be applied to therapeutic discovery. Therefore, cheminformatics played an important role in drug discovery during the pandemic. For instance, according to the report published by the Journal of Cheminformatics in March 2021, the computational chemistry and cheminformatics community was actively involved in COVID-19 research and the rapid onset of computational research on COVID-19. Therefore, such instances indicated considerable growth in the market during the pandemic. Since COVID-19 research studies are still being conducted, there will likely be a continued demand for cheminformatics in the coming years.
The innovations and advancements in the drug development process and increased demand for personalized medicine are the major drivers for the market. Innovations and advancements in the drug development process are prominent market drivers. For instance, according to the Frontiers in Chemistry journal published in June 2021, cheminformatics became an integral part of drug discovery. It accelerated the search for new chemicals with desired physicochemical, pharmacological, toxicological, and pharmacokinetic properties. These are anticipated to propel the market growth over the forecast period.
Furthermore, the new collaborations among the market players increase the widespread applications in cheminformatics. For instance, in March 2021, Elsevier entered a new collaboration with LexisNexis Legal & Professional. It was to strengthen the existing patent coverage in Reaxys, its information solution for chemistry R&D. The content expansion in Reaxys further cements its position as a comprehensive cheminformatics solution by ensuring companies and researchers do not miss key competitive intelligence insights. These are expected to significantly impact the market over the forecast period.
However, a lack of skilled laborers is expected to hinder the market growth over the forecast period.
Virtual screening using cheminformatics approaches became a major tool for identifying leads in drug discovery. Virtual screening can filter unwanted compounds from libraries based on criteria such as solubility and ADMET properties. It can also be used to screen large in silico libraries to identify compounds with desired properties and to gather preliminary information for experimental high-throughput screening. Virtual screening methods include docking calculations if the target structure is known and structural similarity searches if the ligand is known but the target structure is unknown. Quantitative structure-activity relationship (QSAR) modeling if neither structure is known.
The advantages of virtual screening are responsible for propelling segment growth. For instance, according to the report published by Frontiers in Chemistry in April 2021, virtual screening strategies innovated the discovery of new bioactive molecules. It was done by evaluating large libraries of compounds in silico, favoring the analysis of their chemical space, pharmacodynamics, and pharmacokinetic properties. It reduced the financial effort, infrastructure, and time of discovering new chemical entities.
Furthermore, the new advancements in virtual screening are expected to boost the market segment's growth. For instance, the report published by IDTechEx in June 2021 stated that AI in structure-based virtual screening is receiving significant attention from investors as structure-based virtual screening is the leading form of AI in drug discovery. Thus, with new advancements in the segment, the market is expected to grow over the study period.
North America is expected to include a significant share in the market over the forecast period owing to increased funding in biotechnology sectors. It is to accelerate drug discovery, new approvals and launches of various platforms, and the presence of many key players in the region. For instance, in July 2022, Dotmatics launched its small molecule drug discovery solution in the United States. It is an integrated scientific R&D platform with pre-configured workflows and expanded data management capabilities. The Small Molecule Drug Discovery Solution promotes greater collaboration and productivity among research teams, reduces operational inefficiencies, and speeds the process of taking data from insights to decisions. These are expected to boost the market over the study period.
Furthermore, the new collaborations and acquisitions among the region's market players help address various challenges in cheminformatics. For instance, in December 2022, Chemical Computing Group (CCG), headquartered in Montreal, Canada, acquired Discngine SAS. By combining Discngine's technical science capabilities with CCG's market leadership in molecular modeling software, CCG can accelerate the development of life sciences solutions to address key customer challenges, expected to increase the market's growth.
The chemoinformatics market gained significant momentum in research institutions, pharmaceutical companies, the biotechnology industry, research laboratories, and academic institutions. The market is moderately competitive with few market players. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known, including Dassault Systemes, Scilligence, BioSolveIT GmbH, Chemical Computing Group ULC, and Jubilant Biosys Ltd, among others.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook